Cancer Research Annual Meeting 2010  Telomeres
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 10, 629-635, October 1, 1950]
© 1950 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hoagland, M. B.
Right arrow Articles by Hood, M. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hoagland, M. B.
Right arrow Articles by Hood, M. B.

Beryllium and Growth

I. Beryllium-induced Osteogenic Sarcomata*

M. B. Hoagland, M.D., R. S. Grier, M.D. and M. B. Hood, A.B.

(From the Medical Laboratories of the Collis P. Huntington Memorial Hospital of Harvard University, Massachusetts General Hospital, Boston, Massachusetts)

1. Twenty-four rabbits were injected with insoluble beryllium compounds, and seven animals developed osteogenic sarcomas in from 11 to 24 months after injection. These tumors were highly malignant and metastasized rapidly. Seven other injected rabbits—apparently dying of unrelated causes—were found to have remarkably fibrotic and contracted livers.
2. All attempts to transplant these tumors met with failure.
3. The serum alkaline phosphatase activity rose rapidly, paralleling the spread of the tumor throughout the body, and the activity of this enzyme in the tumor tissue itself was extremely high. Magnesium was found to activate, and beryllium to inhibit, the phosphatase associated with the sarcoma in the same manner that these metals affect normal alkaline phosphatase.
4. The importance of an extremely malignant sarcoma produced by a simple metal oxide, in the light of the known effects of beryllium on certain enzyme systems, is discussed.

* This is publication No. 704 of the Cancer Commission of Harvard University. This work was done under U.S. Atomic Energy Commission Contract AT(30-1)609 and, in part, under U.S. Navy Contract N5 ori-76.

Received 5/22/50.


This article has been cited by other articles:


Home page
Arch OphthalmolHome page
I. H. LEOPOLD
PHARMACOLOGY AND TOXICOLOGY
Arch Ophthalmol, August 1, 1951; 46(2): 159 - 224.
[PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1950 by the American Association for Cancer Research.